Jupiter Topco LLC Invests $5.57 Million in Elanco Animal Health Incorporated $ELAN

Key Points

• Jupiter Topco LLC acquired 226,000 Elanco shares worth approximately $5.57 million during the second quarter. Institutional investors collectively own 97.48% of the company.
• Analysts maintain a generally positive view, with a consensus “Moderate Buy” rating and an average price target of $29.09, above the reported opening price of $24.01.
• Elanco exceeded quarterly expectations, reporting $0.34 in EPS versus the $0.27 estimate and $1.37 billion in revenue, up 10.2% year over year. Company insiders also purchased 63,198 shares worth about $1.47 million over the past quarter.

Jupiter Topco LLC acquired a new stake in shares of Elanco Animal Health Incorporated (NYSE:ELAN - Free Report) in the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 226,000 shares of the company's stock, valued at approximately $5,566,000.

Other hedge funds have also made changes to their positions in the company. NewEdge Advisors LLC increased its stake in Elanco Animal Health by 133.7% during the fourth quarter. NewEdge Advisors LLC now owns 1,096 shares of the company's stock valued at $25,000 after acquiring an additional 627 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd. bought a new stake in shares of Elanco Animal Health in the 2nd quarter worth approximately $38,000. Root Financial Partners LLC lifted its position in shares of Elanco Animal Health by 50.7% in the 4th quarter. Root Financial Partners LLC now owns 1,759 shares of the company's stock worth $40,000 after acquiring an additional 592 shares during the period. Uniplan Investment Counsel Inc. acquired a new stake in shares of Elanco Animal Health during the 4th quarter worth approximately $41,000. Finally, Bessemer Group Inc. increased its position in shares of Elanco Animal Health by 33.2% during the first quarter. Bessemer Group Inc. now owns 2,105 shares of the company's stock valued at $50,000 after purchasing an additional 525 shares during the period. Institutional investors own 97.48% of the company's stock.

Analysts Set New Price Targets

A number of research analysts recently commented on the company. Morgan Stanley upped their target price on Elanco Animal Health from $23.00 to $26.00 and gave the company an "equal weight" rating in a research note on Wednesday, July 22nd. Piper Sandler reissued an "overweight" rating on shares of Elanco Animal Health in a report on Monday, June 29th. Wall Street Zen cut shares of Elanco Animal Health from a "strong-buy" rating to a "buy" rating in a research note on Sunday, May 24th. KeyCorp raised their price objective on shares of Elanco Animal Health from $29.00 to $30.00 and gave the stock an "overweight" rating in a report on Thursday, August 6th. Finally, JPMorgan Chase & Co. lifted their target price on shares of Elanco Animal Health from $28.00 to $30.00 and gave the company an "overweight" rating in a research report on Thursday, May 7th. One investment analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $29.09.

Elanco Animal Health Price Performance

Shares of ELAN stock opened at $24.01 on Tuesday. The stock's fifty day simple moving average is $24.62 and its 200 day simple moving average is $23.99. Elanco Animal Health Incorporated has a one year low of $17.11 and a one year high of $27.98. The firm has a market cap of $12.00 billion, a price-to-earnings ratio of -58.56, a P/E/G ratio of 1.44 and a beta of 1.67. The company has a debt-to-equity ratio of 0.58, a current ratio of 2.05 and a quick ratio of 1.10.

Elanco Animal Health (NYSE:ELAN - Get Free Report) last released its quarterly earnings data on Wednesday, August 5th. The company reported $0.34 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.27 by $0.07. The firm had revenue of $1.37 billion during the quarter, compared to analyst estimates of $1.31 billion. Elanco Animal Health had a positive return on equity of 8.13% and a negative net margin of 3.96%.The business's revenue for the quarter was up 10.2% compared to the same quarter last year. During the same period in the prior year, the company posted $0.26 earnings per share. Elanco Animal Health has set its Q3 2026 guidance at 0.190-0.220 EPS and its FY 2026 guidance at 1.100-1.160 EPS. On average, analysts expect that Elanco Animal Health Incorporated will post 1.12 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, insider Shiv O'neill purchased 3,998 shares of the business's stock in a transaction that occurred on Tuesday, August 18th. The stock was purchased at an average cost of $23.58 per share, with a total value of $94,272.84. Following the acquisition, the insider directly owned 87,832 shares of the company's stock, valued at approximately $2,071,078.56. This trade represents a 4.77% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director Michael J. Harrington purchased 5,000 shares of Elanco Animal Health stock in a transaction on Wednesday, August 12th. The stock was purchased at an average price of $21.82 per share, for a total transaction of $109,100.00. Following the completion of the transaction, the director owned 131,451 shares of the company's stock, valued at approximately $2,868,260.82. This represents a 3.95% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders have purchased 63,198 shares of company stock worth $1,473,109 in the last quarter. 1.14% of the stock is owned by corporate insiders.

Elanco Animal Health Company Profile

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco's portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source